Perioperative Toripalimab + Chemo in Stage III Lung Cancer

医学 肺癌 安慰剂 中期分析 内科学 围手术期 化疗 性能状态 外科 肿瘤科 随机对照试验 病理 替代医学
作者
Mark L. Fuerst
出处
期刊:Oncology times [Wolters Kluwer]
卷期号:45 (11): 6-6
标识
DOI:10.1097/01.cot.0000942964.26116.d4
摘要

Lung cancer: Lung cancerAdding toripalimab to perioperative chemotherapy improves event-free survival (EFS) for patients with Stage III resectable non-small cell lung cancer (NSCLC), according to an interim analysis of a randomized, double-blind, placebo-controlled Phase III trial. After a median follow-up of 18.3 months, median EFS was not reached in the toripalimab arm versus 15.1 months in the placebo arm. “A significant improvement in EFS was observed in the toripalimab arm over the placebo,” said lead author Shun Lu, MD, PhD, Chief of the Shanghai Lung Cancer Center at Shanghai Chest Hospital School of Medicine of Shanghai Jiao Tong University in China. “The HR was 0.40, representing a 60 percent risk reduction in disease progression, disease recurrence, or death.” Lu presented the results during the April 2023 American Society of Clinical Oncology (ASCO) virtual plenary session. In addition to improving EFS, toripalimab led to significantly higher rates of major pathologic response (MPR) (48.5% vs. 8.4% with placebo) and pathologic complete response (pCR) (24.8% vs. 1%), and a favorable trend in overall survival (OS), Lu noted. In this analysis of the Neotorch study, 404 patients with Stage III NSCLC in China were randomized to receive either the anti-PD-1 monoclonal antibody toripalimab or a placebo in combination with chemotherapy every 3 weeks for 3 cycles before surgery and 1 cycle after surgery, followed by toripalimab or placebo monotherapy every 3 weeks for 13 cycles. The chemotherapy backbone varied depending on histology of the cancer, with paclitaxel or docetaxel for squamous type disease, and pemetrexed plus platinum for non-squamous type disease. Participation in the study required that patients have EGFR/ALK wild-type, biopsy tissue available for biomarker analysis, measurable lesions, and an ECOG performance status of 1 or less. Patients' baseline characteristics were evenly distributed between the two arms. PD-L1 positivity rate was about 65 percent in both arms and squamous carcinomas were found in 77.7 percent of patients. Two patients had distant metastases at baseline. At the November 30, 2022, data cutoff, the median follow-up was 18.25 months and 144 EFS events were observed. The 1-year EFS rate was 84.4 percent in the toripalimab arm versus 15 percent in the placebo arm. The 2-year EFS was 64.7 percent in the toripalimab arm versus 38.7 percent in the placebo arm. “Patients had a benefit from the toripalimab arm regardless of the PD-L1 expression, while the improvement in the EFS was more predominant in the PD-L1-positive patients,” Lu explained. The hazard ratio was 0.31 for patients with a tumor cell PD-L1 expression more than 1 percent and was 0.59 for those with tumor cell PD-L1 expression lower than 1 percent or nothing available. While OS data are not mature, the median OS was not reached in the toripalimab arm, compared to 30.4 months in the placebo arm, with a hazard ratio of 0.62. After the neoadjuvant therapy, more patients from the toripalimab arm (166 patients) underwent surgery compared to the placebo arm (148 patients). The vast majority (95.8%) of these patients who had surgery achieved R0 resection, which was slightly higher than in the placebo arm. Regarding safety, the incidence of adverse events seemed higher in the toripalimab arm, including Grade 3 or higher adverse events (63.4% vs. 54.0% with placebo), immune-related adverse events (42.1% vs. 22.8%), serious adverse events (40.6% vs. 28.2%), fatal adverse events (0.5% vs. 0%), and adverse events that lead to drug discontinuation (9.4% vs 7.4%). In summary, Lu said: “The addition of toripalimab to chemotherapy provided superior EFS while maintaining a manageable safety profile. Toripalimab demonstrated a higher MPR and pCR, and the OS results show a favorable trend toward toripalimab. The safety profile of the treatment is manageable, and no new safety signal was detected.” In the final analysis, more endpoints will be statistically tested in Stage III or Stage II-III patients' increase in OS. Charu Aggarwal, MD, MPH, ASCO expert in lung cancer and the Leslye M. Heisler Associate Professor of Lung Cancer Excellence at the University of Pennsylvania Perelman School of Medicine, commented: “This study demonstrates a potential new paradigm of perioperative immunotherapy, building upon the current standard of care of neoadjuvant immunotherapy with chemotherapy prior to surgical resection in patients with surgically resectable Stage III non-small cell lung cancer.” Mark L. Fuerst is a contributing writer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
科研通AI6.2的应助被闯天涯采纳,获得10
1秒前
温柔发卡完成签到,获得积分10
3秒前
3秒前
3秒前
科研通AI6.3的应助被壮观雁易采纳,获得10
4秒前
4秒前
4秒前
xieburou完成签到,获得积分10
5秒前
5秒前
生性不爱说话完成签到,获得积分10
6秒前
JamesPei的应助被霁月采纳,获得10
6秒前
852的应助被霁月采纳,获得10
6秒前
ding的应助被霁月采纳,获得10
7秒前
orixero的应助被霁月采纳,获得10
7秒前
7秒前
LL发布了新的文献求助10
8秒前
葱葱完成签到,获得积分10
8秒前
8秒前
聪明的松糕完成签到,获得积分10
8秒前
火山蜗牛完成签到,获得积分10
9秒前
FZ发布了新的文献求助10
9秒前
10秒前
一米阳光完成签到,获得积分10
10秒前
11秒前
小蘑菇的应助被劳小呆采纳,获得10
11秒前
ajing发布了新的文献求助20
12秒前
12秒前
13秒前
科研通AI6.2的应助被XZM采纳,获得10
13秒前
13秒前
sing完成签到 ,获得积分10
14秒前
14秒前
Mortal完成签到 ,获得积分10
15秒前
15秒前
纯真正豪发布了新的文献求助10
17秒前
酷波er的应助被JXY189采纳,获得10
17秒前
17秒前
香蕉觅云的应助被长庚采纳,获得10
17秒前
研友_ngqgY8完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183667
求助须知:如何正确求助?哪些是违规求助? 9572953
关于积分的说明 21828185
捐赠科研通 7780853
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558251
邀请新用户注册赠送积分活动 2480500